The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Int J Clin Oncol
; 28(3): 427-435, 2023 Mar.
Article
in En
| MEDLINE
| ID: mdl-36580184
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostate-Specific Antigen
/
Prostatic Neoplasms, Castration-Resistant
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Int J Clin Oncol
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article
Affiliation country:
Japan
Country of publication:
Japan